Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: CPOP-R vs CHOP-R in Diffuse Large B-Cell Lymphoma
NCT00268853Phase 2Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Nov 2005
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of pixantrone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Response Rate at 5 years. Started Nov 2005; status: completed.
02
Drugs
pixantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00268853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268853.